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Background: Very few studies have been carried out so far aiming at modulating cellular immune responses in
dogs. In this study, we evaluated the ability of recombinant canine IL-2 (rcaIL-2) and IL-12, in the form of a
single-chain fusion protein (rsccaIL-12), to stimulate peripheral blood mononuclear cells (PBMC) of healthy mongrel dogs.
Results: Recombinant canine IL-2 purified from Escherichia coli or present in the supernatant of COS-7 cells transfected with
pcDNA3.1-caIL-2 (COS-7 caIL-2 supernatant) was able to induce proliferation of CTLL-2 cells, thus showing their functional
activity. In addition, purified rcaIL-2 and COS-7 caIL-2 supernatant stimulated resting canine PBMC proliferation to a level
higher than baseline level. Neither COS-7 sccaIL-12 supernatant nor COS-7 caIL-2 supernatant alone was able to induce
significant production of interferon gamma by resting PBMC. However, COS-7 sccaIL-12 supernatant in combination
with COS-7 caIL-2 supernatant induced production of IFN-γ by those cells.
Conclusions: The data shown herein suggest that the combination of canine recombinant IL-12 and IL-2 can be useful
to promote cellular immune responses in dogs.
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Cytokines are proteins or glycoproteins produced mainly
by cells of the immune system. They participate in sev-
eral different biological processes, including the homeo-
stasis of the immune system and the generation of
immune responses [1,2]. To exert their biological activ-
ities, cytokines bind to specific receptors on the cyto-
plasmic membrane of the target cells and activate
intracellular signaling pathways that result in the gener-
ation of transcription factors and expression of several
genes [3]. Being involved in the initiation, effector mech-
anisms and regulation of inflammation, as well as in the* Correspondence: ggileno@bahia.fiocruz.br
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velopment and control of many different diseases, in-
cluding the infectious, parasitic, allergic, autoimmune
and neoplastic diseases. Therefore, substances that inter-
fere with cytokine signaling pathways, both agonists and
antagonists, may be useful for the prophylaxis or therapy
of a great number of diseases.
There is a large amount of data showing that the ma-
nipulation of the immune system by interference in
cytokine signaling changes the outcome of various dis-
eases in the murine model. However, no studies compar-
able to those carried out in mice that could encourage
the development of new therapeutic approaches for ca-
nine diseases have been reported in the dog.
The control of infection by intracellular pathogens can
be initiated by stimulation of natural killer (NK) cells and
be established by cellular immune responses involving
CD4+ T cells, activation of macrophages, and CD8+ T cellsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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mote cellular immune responses in dogs.
Interleukin-2 (IL-2) was the first cytokine to be tested
in a purified state or cloned [5,6]. IL-2 is produced
mainly by CD4+ T cells and CD8+ T cells activated by
antigen [7,8]. It performs various activities in the im-
mune system, including promotion of differentiation of
CD4+ T helper-1 (Th1) and −2 (Th2) cells, maintenance
of CD4+ regulatory T (Treg) cells and optimization of
the expansion of CD8+ effector T cells and CD8+ mem-
ory T cells [9].
IL-12 is a heterodimeric cytokine produced by antigen-
presenting cells (dendritic cells, macrophages and B cells)
that, alone or synergistically with other factors, e.g., IL-2
or mitogens, displays the ability to stimulate the produc-
tion of interferon gamma (IFN-γ) in resting or activated
NK and T cells [10]. IL-12 is also able to promote the
cytotoxic activity and proliferation of NK and T cells [10].
Furthermore, IL-12 contributes to the generation of Th1
lymphocytes [11], which are required for controlling infec-
tions by intracellular pathogens.
Although several authors have reported some conse-
quences of the exposure of recombinant human IL-2
(rhuIL-2) or IL-12 (rhuIL-12) on canine systems in vitro
and in vivo [12-18], reports on the exposure of canine
cells to recombinant canine IL-2 (rcaIL-2) do not exist
and to recombinant canine IL-12 (rcaIL-12) still provide
insufficient knowledge to allow for the exploitation of
the full potential of this cytokine in the manipulation the
immune system of dogs [19-23]. The administration of
heterologous cytokines in animals, even when the hom-
ology between the donor and receptor species is high,
may result in the production of specific antibodies with
the potential ability to prevent the action of long-lasting
treatments [24-26]. Therefore, in order to manipulate the
canine immune system for long-term, it would be better
to use homologous instead of heterologous cytokines.
Since IL-2 synergizes with IL-12 to promote NK and T
cell proliferation, cytotoxic activity, and IFN-γ produc-
tion [27-30], it would be interesting to study the effects
of the combination of these two cytokines in dogs. In
this paper, cloning of canine IL-2, expression of rcaIL-2
and rcaIL-12 and the ability of these cytokines to stimu-
late canine PBMC are reported.
Methods
Cloning, production and purification of canine IL-2
The cDNA of canine IL-2 was inserted into a plasmid ei-
ther for expression in Escherichia coli or in mammalian
cells, using conventional methods. Briefly, the cDNA en-
coding the mature protein was amplified by PCR from a
pCRII-2-caIL-2 template (kindly donated by Dunham,
Department of Veterinary Pathology, University of Glas-
gow Veterinary School, United Kingdom) with specificprimers (forward 5′-CGCGGATCCGGCACCTATTACT
TCAAG and reverse 5′-CCGGAATTCTCAAGTCAGT
GTTGAG) and digested. The digestion product was
inserted into pRSET (Invitrogen Corporation, Carlsbad,
EUA) using the BamHI/EcoRI site, generating the pRSET-
caIL-2 construction.
The cDNA encoding the whole IL-2 protein was amp-
lified by RT-PCR from canine PBMC, after their stimula-
tion with 10 μg/mL concanavalin A (Con A, Sigma-
Aldrich, St. Louis, USA) for 24 h at 37°C in a 5% CO2
atmosphere, using specific primers (forward 5′-CGCG
GATCCAAGCCACCATGGGCAAAATGCAACTCTTG
TCTTGC and reverse 5′-CCGGAATTCTCAAGTCAG
TGTTGAGAAGATGC). The cDNA was digested and
inserted into the BamHI/EcoRI site of the pcDNA3.1
plasmid (Invitrogen), resulting in the construction
pcDNA3.1-caIL-2.
The plasmid DNA molecules with the inserts were se-
quenced in an ABI3100 automatic sequencer (Applied
Biosystems, Foster City, CA, USA).
The production of rcaIL-2 was performed in BL21
strain (DE3)pLysS E. coli (Invitrogen) transformed with
pRSET-caIL-2 following the manufacturer’s recommen-
dations. The bacterial cell pellet, obtained by centrifuga-
tion after inducing the protein expression for 5 h with
1 mM isopropyl-β-D-thiogalactoside (IPTG), was sus-
pended in 50 mM Tris, pH 7.6, containing 1% Triton
X-100 (v/v) and 1 mg/mL lysozyme. The suspension
was then subjected to ultrasonication. The inclusion
bodies were collected by centrifugation, solubilized in
20 mM Na2HPO4, 500 mM NaCl, 10 mM imidazole
and 8 M urea, pH 7.4, and purified in a nickel-Sepharose af-
finity column (Amersham Biosciences, Uppsalla, Sweden),
following the manufacturer’s recommendations. The puri-
fied protein was refolded using the dialysis method de-
scribed by Guisez and collaborators [31] and the protein
concentration was determined by Bradford’s method.
The purity of the affinity-purified IL-2 was assessed by
polyacrylamide gel electrophoresis in the presence of so-
dium dodecyl sulfate (SDS- PAGE) and by Western blot
using anti-histidine monoclonal antibody (Invitrogen).
His-tagged recombinant green fluorescent protein (EGFP),
produced in BL21(DE3)pLysS E. coli, and chromatographi-
cally affinity purified, was used as a positive control.
To promote stability of the purified protein, bovine
serum albumin was added to achieve a final concentra-
tion of 1 mg/mL [31]. Aliquots were prepared and
stored at −20°C until use.
Expression of canine IL-2 and IL-12 in eukaryotic cells
Recombinant canine IL-2 and IL-12 were separately
expressed into culture supernatants of COS-7 cells trans-
fected with pcDNA3.1-caIL-2 or pcDNA3.1-sccaIL-12,
using the method previously described [20]. The latter
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protein [20]. Supernant of COS-7 cells transfected for
48 h with pcDNA3.1-caIL-2 (COS-7 caIL-2 SN), pcDNA3.1-
sccaIL-12 (COS-7 sccaIL-IL-12 SN) or pcDNA3.1 without
insert (COS-7 SN-negative control) were collected and
stored at −20°C until use.Assessment of biological activity of recombinant canine
IL-2 (rcaIL-2)
The biological activity of rcaIL-2 produced in E. coli or
COS-7 cells was evaluated using CTLL-2 cells (TIB-214
cells, American Type Culture Collection, ATCC, USA),
essentially as previously described [32]. Briefly, in tripli-
cate wells of 96-well flat bottom microtiter plates (Corn-
ing Incorporated), 104 CTLL-2 cells/well in RPMI 1640
culture medium supplemented with 2 mM of sodium
pyruvate, 2 mM of L-glutamine and 10% fetal calf serum
(supplemented RPMI 1640) were cultured with: 1)
rcaIL-2 purified from E. coli at final concentrations be-
tween 9 pg/mL and 700 ng/mL; 2) COS-7 caIL-2 SN
or SN COS-7-negative control at final concentrations
between 0.39 and 12.5%; 3) supernant of rat spleno-
cytes stimulated with Con A), the so-called T-STIM
(BD Biosciences, Franklin Lakes, NJ, USA) at 10% (posi-
tive control); and 4) supplemented RPMI 1640 culture
medium. The plates were incubated for 24 h at 37°C in a
humidified atmosphere of 5% CO2. Thirty μL of supple-
mented RPMI medium containing 1 μCi of 3H-thymidine
were then added to each well. After a further 24 h period
of incubation, the cells were collected onto glass fiber
membranes (Packard , Meriden, USA) and analyzed in a
Matrix 9600 Direct Beta Counter (Packard), that gener-
ated counts per minute (CPM) values related with beta
particle emission.Canine peripheral blood mononuclear cells (PBMC)
Eight healthy adult mongrel dogs, 4 males and 4 females,
were used. The animals were kept in the Gonçalo Moniz
Research Center kennel with access to water and food
ad libitum. All experiments were performed in accord-
ance with the guidelines of the Oswaldo Cruz Founda-
tion experimental animal use (Gonçalo Moniz Research
Center Ethical Committee Experimental Licence Proto-
col 040-CPqGM). Twenty-five mL of blood from each
dog were collected from the cephalic vein with a hepa-
rinized syringe (Heparin, Eurofarma, São Paulo, Brazil).
Blood samples, diluted 1:2 in Hanks solution (HBSS,
Sigma-Aldrich) buffered with 10 mM HEPES (Invitro-
gen), pH 7.0, were placed onto Fycoll-Hypaque (Sigma-
Aldrich) and centrifuged for 35 minutes at 800 × g, at
20°C. The mononuclear cells were collected, washed twice
with buffered HBSS and suspended in RPMI 1640 supple-
mented with 10 mM HEPES, 10 μM 2-mercaptoethanol(complete RPMI 1640) and 50 μg/mL gentamicin sulfate
(New Farma Ltda., Anapolis, Brazil) to 2 × 106/mL.
Peripheral blood lymphocyte proliferation after
stimulation with rcaIL-2 or COS-7 caIL-2 SN
One hundred μL suspensions of 2 ×105 PBMC of 6 dogs
were added in triplicates to wells of 96-well flat-bottom
microtiter plates. To each well it was also added a
100 μL volume of: 1) rcaIL-2 produced in E. coli, to
reach a final concentration of 50 ng/mL; 2) complete
RPMI 1640; 3) COS-7 caIL-2 SN or COS-7 SN-negative
control, to achieve a final concentration of 0.5, 5 and
50%. The plates were incubated at 37°C in a humidified
atmosphere of 5% CO2 for 4, 6, 8, 10, 12 or 14 days.
Eighteen hours before harvesting the cells, 30 μL of
RPMI 1640 with 1 μL Ci 3H-thymidine were added to
each well. The cells were collected and evaluated as de-
scribed above.
Detection of interferon gamma in cultures of PBMC
stimulated with IL-12 and/or IL −2
One hundred μL of a suspension of 2 ×105 PBMC were
added to each well of 96-well flat-bottom microtiter
plates. It was also added to the same wells, in triplicate,
100 μL volumes of: 1) complete RPMI 1640; 2) Con A at
5 μg/mL; 3) COS-7 caIL-2 SN at 25%; 4) COS-7 sccaIL-
12 SN at 0.025, 0.5 or 10%; or 5) COS-7 sccaIL-12 SN at
0.025, 0.5 or 10% combined with COS-7 caIL-2 SN at
0.02, 1, 5, or 25%. The plates were incubated for 48 h at
37°C in a humidified atmosphere with 5% CO2. The cul-
ture supernatants were removed and stored at −20°C
until use. The concentration of interferon gamma (IFN-γ)
was measured in the supernatant by capture ELISA, using
reagents from R&D Systems (Minneapolis, USA) and
following the manufacturer’s recommendations. Briefly,
96-well high-binding microtiter plates (Corning Incorpo-
rated Life Sciences) were coated with 100 μL/well of anti-
canine IFN-γ at 2 μg/mL and blocked with 300 μL/well of
1% bovine serum albumin (BSA), 5% sucrose, and 0.05%
NaN3 in PBS. One hundred μL of the test samples were
applied in duplicates to the wells. For the elaboration of a
calibration curve, recombinant canine IFN-γ was used in
duplicate at concentrations between 62.5 pg/mL to 16 ng/
mL. The following reagents were successively applied: a)
anti-canine IFN-γ - biotin conjugate at 100 ng/mL; 2)
streptavidin-peroxidase conjugate diluted 1:200; and 3)
tetramethylbenzidine substrate (Sigma- Aldrich). The re-
action was stopped by adding 50 μL/well of 1 M H2SO4
and the plates were analyzed at 450 nm in an Emax Preci-
son Microplate Reader (Molecular Devices Corporation,
Sunnyvale, USA). The concentration of canine IFN-γ
present in each sample was estimated using the Softmax
3.0 program, corrected for the dilution factor when
needed.
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For the lymphoproliferation assays, the medians of CPM
were compared using the non-parametric Friedman test
followed by the Dunn’s test, since CPM data correspond-
ing to thymidine incorporation generally does not have a
normal distribution. The values for IFN-γ concentration
were compared by ANOVA and Dunnett’s post-test.
Values of p < 0.05 were considered significant.Results
Cloning of canine IL-2 and production in E. coli
The DNA sequencing of pRSET-caIL-2 construction in-
sert showed two nucleotide mutations at positions 187
(T= > C) and 243 (A= > G), in comparison with the
cDNA encoding the full-length protein previously de-
scribed by Dunham and collaborators [33], resulting in a
substitution of a phenylalanine for a leucine (F = > L)
residue. This corresponds to a change of the 43rd amino
acid residue in the mature protein, and the resulting re-
combinant protein was called rIL-2-F43L.
The DNA sequencing of pcDNA3.1-caIL-2 construc-
tion insert revealed a complete identity with cDNA en-
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Figure 1 Evaluation of rcaIL-2 expression and affinity purification by
polyacrilamide gel stained with Commassie blue. Lane 1, Molecular weight
BL21(DE3)pLysS-pRSET-caIL-2; Lane 4, affinity purified rcaIL-2-F43L. B. Sampl
antibody conjugated with alkaline phosphatase. Lane 1, E. coli BL21(DE3)pLysS
affinity purified rcaIL-2-F43L; and Lane 4, affinity purified His-tagged enh
and arrow head indicate rcaIL-2F43L and EGFP bands, respectively.and collaborators [33], with the exception of the nucleo-
tide at position 4 (T= > G), deliberately changed to intro-
duce the consensus eukaryotic ribosome binding site
sequence [34].
Canine rIL-2-F43L with an N-terminus histidine tag,
produced in E. coli and purified by affinity chromatog-
raphy, displayed a single band with a molecular weight
of 19.3 kDa in SDS-PAGE and Western blot analysis
(Figure 1).Biological activity of cloned canine IL-2
To assess whether the canine rcaIL-2-F43L subjected to
refolding or the COS-7 caIL-2 SN would present bio-
logical activity, the CTLL-2 cell proliferation assay was
performed, and median (M) values of CPM, that are re-
lated to thymidine incorporation, were used to analyze
the results. CTLL-2 cells cultured in supplemented
RPMI 1640 medium alone (negative control) or stimulated
with 10% T-STIM (positive control) showed no (M= 14.0)
or high (M = 73,166) proliferation activity, respectively.
CTLL-2 cells cultured with rcaIL-2-F43L in concentrations
ranging from 0.22 ng/mL (M= 413) to 700 ng/mL (M=










SDS-PAGE and Western blot. A. Samples analysed in 15%
markers; Lane 2, E. coli BL21(DE3)pLysS-pRSET without insert; Lane 3,
es evaluated by Western blot developed with an anti-His tag monoclonal
-pRSET without insert; Lane 2, BL21(DE3)pLysS-pRSET-caIL-2; Lane 3,
anced green fluorescent protein (EGFP, positive control). Arrows
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However, the proliferation peak was reached when rcaIL-2-
F43L was used at 140 ng/mL (M= 20,380) (Figure 2A).
COS-7 cells caIL-2 SN also induced proliferation of
CTLL-2 cells when used at concentrations ranging from
0.39% (M = 2,272) to 12.5% (M = 21,110), as compared
with cells incubated with COS-7 SN-negative control
(highest value of M = 10) (Figure 2B). Interestingly, the
proliferation peak was reached with COS-7 caIL-2 SN at
6.25% (M = 25,068) (Figure 2B). These data indicated
that both the recombinant protein produced in E. coli
and refolded and the one produced in COS-7 cells is
functionally active.
Proliferation of resting PBMC stimulated with cloned
canine IL-2
To determine if the rcaIL-2 produced in E. coli or the
COS-7 caIL-2 SN would promote proliferation of resting


















Figure 2 Evaluation of CTLL-2 proliferation following stimulation
with recombinant canine IL-2 produced by E. coli or COS-7 cells.
CTLL-2 cells were cultured for 48 h with: (A) different concentrations of
affinity purified rcaIL-2-F43L produced in E. coli or (B) different
concentrations of supernatant of COS-7 cells transfected with
pcDNA3.1 without insert (circles) or pcDNA3.1-caIL-2 (squares).
The cells were pulsed with 3H-thymidine for 24 h. The data represent
the median of CPM of triplicates and the bars the 25 and
75 percentiles.for 4 to 14 days with rcaIL-2-F43L at 50 ng/mL or COS-
7 caIL-2 SN at 0.5, 5 or 50% and thymidine incorporation
was measured. Whereas PBMC cultured in complete
RPMI medium alone, used to determine the basal prolifer-
ation, presented low incorporation of thymidine, with
CPM values ranging from M= 9 to M = 31 along the time
points assessed, cells cultured with rcaIL-2-F43L displayed
significantly higher CPM values at days 8 (M= 3,542), 10
(M= 7,854) and 12 (M= 11,928), corresponding to an in-
crease of up to 918 times above the basal levels (p < 0.05,
Dunn’s test; Figure 3A). Moreover, the PBMC incubated
with COS-7 caIL-2 SN showed significantly higher thymi-
dine incorporations when tested at 0.5% for 8 days (M =
237 vs 14 for the control) and 12 days (262 vs 10) , 5% for
6 days (388 vs 22), 8 days (2,161 vs 26) and 10 days (2,375
vs 28), and 50% for 8 days (780 vs 26) and 10 days (735 vs
32), reaching up to an 87-fold increase, as compared with
the COS-7 SN-negative control (Dunn’s test p <0.05,
Figure 3B, C and D).
Production of IFN-γ by canine PBMC stimulated with
recombinant homologous IL-12 and/or IL-2
To evaluate the ability of the recombinant IL-12 and/or
IL-2 to stimulate the production of IFN-γ by canine
cells, PBMCs from 8 healthy dogs were cultured with
different concentrations of COS-7 sccaIL-12 SN com-
bined or not with various concentrations of COS-7 caIL-2
SN for 48 h. The concentration of IFN-γ (mean ± standard
deviation) in the supernatant of PMBC cultures carried
out with complete RPMI 1640 alone or with the addition
of 5 μg/mL Con A was 0.19 ± 0.26 and 30.08 ± 22.56 ng/
mL, respectively. PBMC stimulated with only COS-7
sccaIL-12 SN at 0.025% (1.56 ± 2.31 ng/mL), 0.5% (2.36 ±
3.74 ng/mL), 10% (2.14 ± 2.50 ng/mL) or COS-7 IL-2 SN
at 25% (0.52 ± 0.93 ng/mL) produced a greater amount of
IFN-γ compared with the cells cultivated with complete
RPMI 1640 alone. However, the differences were not sig-
nificant, probably because only PBMC of 3 or 4 out of 8
dogs and only 1 out of 8 dogs responded to the stimulus
of IL-12 and IL-2, respectively (Figure 4). Nevertheless,
when PBMC were stimulated with a combination of COS-
7 sccaIL-12 SN at either 0.025% (11.34 ± 11.09 ng/mL),
0.5 (13.69 ± 12.62 ng/mL) or 10% (12.73 ± 13.57) and
COS-7 caIL-2 SN at 25% or with a combination of COS-7
sccaIL-12 SN at either 0.025 (9,22 ± 10,70 ng/mL) or 0.5%
(16,33 ± 16,69 ng/mL) and COS-7 caIL-2 SN at 5%, a
significant higher production of IFN-γ was detected
(p < 0.05, Dunnett’s test; Figure 5). The combined in-
citation of IL-12 and IL-2 resulted in the response of 6
or 7 out of 8 dogs.
Discussion
In the present work, we have reported the construction





































Figure 3 Evaluation of proliferation of canine peripheral blood mononuclear cells (PBMC) stimulated with recombinant canine IL-2
produced by E. coli or COS-7 cells. PBMC of 6 adult mongrel dogs were cultured for 4 to 14 days with: (A) affinity purified rcaIL-2-F43L produced
in E. coli at 50 ng/mL (squares) or excipient (circles); (B, C, and D) supernatant of COS-7 cells transfected with either pcDNA3.1 without insert (circles)
or pcDNA3.1-caIL-2 (squares) at 0.5% (B), 5% (C) or 50% (D). The cells were pulsed with 3H-thymidine for 18 h. The data represent the median of the
CPM obtained for the six animals and the bars the 25 and 75 percentiles. *p < 0.05, **p < 0.01; Dunn’s post-test (p < 0.001, Friedman’s test).
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eukaryotic cells (pcDNA3.1caIL-2), respectively. Com-
paring the inserts of the constructions pRSET-caIL-2
and pcDNA3.1-caIL-2 with DNA encoding wild-type ca-
nine IL-2, previously described by Dunham and collabora-
tors [33], two nucleotide point mutations and complete
identity, respectively, was observed. One of the mutationsM Con A 25









Figure 4 Interferon gamma (IFN-γ) production by peripheral
blood mononuclear cells (PBMC) stimulated with recombinant
canine IL-2 or IL-12 produced by COS-7 cells. PBMC of 8 adult
mongrel dogs were cultured for 48 h with: complete RPMI 1640
medium alone (M), concanavalin A at 5 mg/mL, supernatant of
COS-7 cells transfected with pcDNA3.1-caIL-2 (SN IL-2) at 25% or
supernatant of COS-7 cells transfected with pcDNA3.1-sccaIL-12
(SN IL-12) at 0.025, 0.5 or 10%. IFN-γ was assessed in the PBMC
supernatants by capture ELISA. Data represent average of duplicates
and bars the means obtained for the eight animals. *p < 0.01, Dunnett’s
test (p < 0.0001, repeated measures ANOVA).detected in insert of pRSET-caIL-2 was conservative
(change to amino acid with similar characteristics) and the
other was silent. These mutations have probably occurred
due to error in the incorporation of nucleotides carried
out by the Taq polymerase used in the PCR reaction [35].
However, it is unlikely that the conservative change of a
single amino acid residue would influence too much on
the physicochemical characteristics of the protein and
interfere with its biological properties. In fact, to deter-
mine the impact of such mutation, a tridimensional struc-
ture model of canine rcaIL-2-F43L was made using tools
of the Swiss Model (http://swissmodel.expasy.org/) and
PyMol software (http://www.pymol.org/) and crystallized
human IL-2 (pdb IM47) as a reference protein. The tri-
dimensional structure model of rcaIL-2-F43L and hu-
man IL-2 showed no significant differences one from
another (data not shown).
The pRSET-caIL-2 construction induced the produc-
tion of rcaIL-2-F43L in the form of inclusion bodies in
E. coli [36]. In order to refold the rIL-2-F43L, the in-
clusion bodies were solubilized with a buffer contain-
ing urea, the protein was affinity purified and subjected to
dialysis to slowly remove the chaotropic agent and allow
the formation of the disulfide bridge between the cysteines
at positions 59 and 107 of the mature protein (which cor-
responds to the bridge between amino acid 58 and 105 of
the human homologous protein), using a previously de-
scribed method [31]. This disulfide bridge favors the
stabilization of the molecule [33,37,38]. Unfortunately,
after being subjected to refolding, the rcaIL-2-F43L showed
some degree of instability and a progressive reduction in
the concentration of soluble protein in the recombinant


























Figure 5 Interferon gamma (IFN-γ) production by peripheral blood mononuclear cells (PBMC) stimulated with recombinant canine IL-2
and/or IL-12 produced by COS-7 cells. PBMC of 8 adult mongrel dogs were cultured for 48 h with: a) complete RPMI 1640 medium alone (M),
b) supernatant of COS-7 cells transfected with pcDNA3.1-caIL-2 (SN IL-2) at 0, 0.2, 1, 5 or 25% in combination with supernatant of COS-7 cells
transfected with pcDNA3.1-sccaIL-12 at 0.025 (A), 0.5 (B) or 10% (C). IFN-γ was assessed in the PBMC supernatants by capture ELISA. Data
represent average of duplicates and bars the means obtained for the eight animals. *p < 0.05, **p < 0.01; Dunnett’s test (p < 0.0001, repeated
measures ANOVA).
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stored at -20o C (data not shown). This may have hap-
pened by adherence of part of the protein to the tube used
for storage or aggregation. Interestingly, the canine IL-2
recently produced in our laboratory using the baculovirus/
insect system seemed to be stable during storage at -20°C
(unpublished results).
Cerruti-Sola and collaborators [32] have previously re-
ported that the native canine IL-2 was able to induce
proliferation of CTLL-2 cells [39], a murine IL-2-
dependent CD8+ T cell line. In the current work,
rcaIL-2F43L or COS-7 caIL-2 SN stimulated the prolif-
eration of CTLL-2 cells in a dose-dependent manner,
indicating that the cytokine produced in E. coli and
COS-7 cells is biologically active. The maximal prolif-
eration induced by rcaIL-2-F43L or COS-7 caIL-2 SNwas lower than that promoted by T-STIM. This prob-
ably happened due to the fact that, in addition to IL-2,
the latter contains other(s) factor(s), including IL-4,
also capable of stimulating CTLL-2 cell proliferation
[40]. Interestingly, the highest concentration of either
rcaIL-2F43L (700 ng/mL), COS-7 caIL-2 SN [50 or
25% (data not shown) and 12.5%] or T-STIM (50%,
data not shown) stimulated the proliferation of CTLL-
2 cells at a lower level than the maximum. This is
probably due to an inhibitory activity of high concen-
trations of IL-2, or other factors present in the SN, as
previously described for human lymphocytes [41].
Several authors have reported that resting NK cells,
CD4+T lymphocytes, and CD8+ T lymphocytes from
peripheral blood could proliferate when stimulated with
rhuIL-2 or recombinant murine IL-2 [12,42-45]. In fact,
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or high affinity IL-2 receptor, including NK cells, NKT
cells, regulatory T cells and CD8+ memory T cells (reviewed
in [46]), have the potential to proliferate when stimulated
in vitro without the need of an additional spur.
To determine whether recombinant canine IL-2 could
also induce proliferation of resting lymphocytes, PBMC
from six healthy dogs were cultured for 4 to 14 days
with rcaIL-2-F43L at 50 ng/mL or with COS-7 caIL-2 SN
(0.5, 5 or 50%). Indeed, after 6 to 12 days of stimulation,
the peripheral blood lymphocytes showed a proliferative
response. Previously, Helfand and collaborators, in 1992,
reported similar results using rhuIL-2 at 25 U/mL on
PBMC of five healthy dogs, showing an increase of
proliferation starting by day 5 and peaking by day 8 to 10
of culture [12].
IL-12 stimulates the production of IFN-γ by NK cells
and T cells and thereby favors the development of Th1 im-
mune responses (reviewed in [11]). In addition, rhuIL-2
synergizes with IL-12 in the production of IFN-γ in
humans [27,28].
To determine the capacity of canine IL-12 and/or ca-
nine IL-2 to promote production of IFN-γ, PBMC from
eight healthy dogs were cultured with COS-7 sccaIL-12
SN (0.025, 0.5 or 10%) or COS-7 caIL-2 SN (25%) or the
combination of COS-7 sccaIL-12 SN (0.025, 0.5 or 10%)
and caIL-2 SN (0.2, 1, 5 or 25%). Interestingly, only
around half and the minority of the dogs produced IFN-
γ after the stimulation with COS-7 sccaIL-12 SN alone
or COS-7 caIL-2 SN alone, respectively, in comparison
with the COS-7 SN-negative control. However, when
COS-7 sccaIL-12 SN (0.025, 0.5 or 10%) was used in
combination with COS-7 caIL-2 SN (5 or 25%), PMBC
of the majority of dogs synthesized IFN-γ. Such a re-
sponse to IL-12 and/or IL-2 seems to be very heteroge-
neous in the population of dogs studied. The data
shown herein are in agreement with reports suggesting
that IL-2 alone induces the production of IFN-γ in hu-
man cells only when used at high concentrations
(above 100 U/mL, corresponding to 10 ng/ml) [43,45]
and IL-12 by itself promotes the synthesis of low
amounts of IFN-γ in lymphocytes [23,27,29,47].
The results described in this study encourage the evalu-
ation of the effects of the administration of rsccaIL-12
and/or rcaIL-2 in dogs, aiming at modulating their im-
mune system, for the development of prophylactic and
therapeutic protocols for various diseases. In such studies,
low doses of IL-2 and IL-12 could be used in combination,
resulting in little toxicity. Those doses alone would be in-
effective but, in combination, would promote desirable
biological effects [48]. For this, rcaIL-2 produced in the
baculovirus/insect cell system (BEV) (unpublished results)
and rsccaIL-12 also produced in BEV (manuscript in prep-
aration) could be used. In addition, it would be interestingto determine which are the peripheral blood lymphocyte
subpopulations that synthesize interferon gamma when
stimulated in vitro by the recombinant canine cytokines.
This could be achieved by culturing the cells, either in
bulk or separated in subpopulations, staining them with
anti-cytokine and anti-lymphocyte subpopulation markers
fluorescent antibodies and analyzing them by flow
cytometry.
An undesirable effect that may result from the use of
IL-12 alone or in combination with IL-2, hampering the
development of cellular immune responses, would be
the expression of IL-10 [49]. Indeed, several authors
have reported that treatment with IL-12 and/or IL-2
promotes IL-10 synthesis in T cell clones (Th0, Th1, and
Th2), and in peripheral blood cells co-stimulated with
anti-CD3 or Con A, in mice [50-52]. Therefore, perhaps,
the use of IL-12 and/or IL-2 should be combined with
some sort of strategy for blocking IL-10 stimulation,
such as the utilization of antagonist peptides, aptamers
[53-55], neutralizing antibodies for IL-10 or for the
IL-10 receptor (IL-10R1) [56,57], and soluble IL-10
receptor (sIL-10R1) [58,59].
Conclusions
The results presented herein suggest that the combin-
ation of recombinant canine IL-12 and IL-2 can be use-
ful to promote cellular immune responses in dogs.
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